March 27, 2019
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
Mr. Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller at...
Read Press ReleaseDermavant’s
Growing Pipeline
Dermavant is developing investigational drugs to treat atopic dermatitis, acne, hyperhidrosis and other inflammatory skin diseases and medical dermatologic conditions.
Patient-Focused
Innovation
The patient is at the heart of everything we do. It is for them that we harness scientific innovations to provide new treatment options for inflammatory skin diseases and medical dermatologic conditions with unmet medical needs.
March 27, 2019
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
Patient-Focused
Innovation
The patient is at the heart of everything we do. It is for them that we harness scientific innovations to provide new treatment options for inflammatory skin diseases and medical dermatologic conditions with unmet medical needs.
